Virologic response maintenance and hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir
CONCLUSIONS: Our study indicated an elevated HCC probability for entecavir-treated CHB patients with Non-MVR, especially for those with cirrhosis or a high predicted score at baseline. For MVR patients, the trajectories of ALT after virologic response suggested different HCC risks.PMID:34511012 | DOI:10.1080/17474124.2021.1980385
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Authors: Xiaomo Wang Yu Chen Manman Xu Kailiang Cheng Xiaoman Duan Wei Liao Yanhong Wang Ying Lu Zhongping Duan Li Wang Source Type: research
More News: Cancer & Oncology | Carcinoma | China Health | Cirrhosis | Gastroenterology | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Hong Kong Health | Liver Cancer | Study | Virology